Neurocrine Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Neurocrine Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Neurocrine Biosciences Inc Strategy Report
- Understand Neurocrine Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Neurocrine Biosciences Inc (Neurocrine) is a biopharmaceutical company that discovers, develops, and markets neurological drugs. The company’s lead product Ingrezza, is a vesicular monoamine transporter 2 (VMAT2) inhibitor to treat adults with tardive dyskinesia and chorea associated with Huntington’s disease. It is developing a pipeline of drug candidates for various indications in neurology, neuroendocrinology, and neuropsychiatry. Neurocrine also conducts clinical trials and studies for diseases such as movement disorders, epilepsy, and congenital adrenal hyperplasia, among others. The company works in collaboration with Mitsubishi Tanabe Pharma and AbbVie for products distribution. Neurocrine is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
12780 El Camino Real, San Diego, California, 92130-2042
Website
www.neurocrine.com
Telephone
1 858 6177600
No of Employees
1,400
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NBIX (NASD)
Revenue (2022)
$1.9B
26.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
61.6%
(2022 vs 2021)
Market Cap*
$13.5B
Net Profit Margin (2022)
XYZ
27.5%
(2022 vs 2021)
* As of and is in US$
Neurocrine Biosciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ongentys (Opicapone) Capsules | Ingrezza |
| Ingrezza (Valbenazine) Capsules | Ongentys |
| Orilissa Tablets | Efmody |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company and Biocytogen Pharmaceuticals entered into an antibody evaluation and option agreement to secure a grant for the access of Biocytogen’s fully human antibodies against multiple specified targets. |
| 2023 | Plans/Strategy | In December, the company announced its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies. |
| 2023 | New Products/Services | In November, the company launched DISCOVER TD, a digital tool designed to help healthcare providers learn about and identify tardive dyskinesia. |
Competitor Comparison
| Key Parameters | Neurocrine Biosciences Inc | Pfizer Inc | Eli Lilly and Co | Newron Pharmaceuticals SpA | Auspex Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Italy | United States of America |
| City | San Diego | New York | Indianapolis | Bresso | La Jolla |
| State/Province | California | New York | Indiana | - | California |
| No. of Employees | 1,400 | 88,000 | 43,000 | 23 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William H. Rastetter, Ph.D. | Chairman | Executive Board | 2011 | 74 |
| Kevin C. Gorman, Ph.D. | Director; Chief Executive Officer | Executive Board | 2008 | 65 |
| Matthew C. Abernethy | Chief Financial Officer | Senior Management | 2017 | 43 |
| Kyle W. Gano, Ph.D | Chief Business Development Officer; Chief Strategy Officer | Senior Management | 2020 | 50 |
| Darin M. Lippoldt | Secretary; Chief Legal Officer | Senior Management | 2014 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward